Khan Sajjad Ali, Ram Nanik, Masood Muhammad Q
Department of Medicine, Section of Endocrinology, Aga Khan University Hospital, Karachi, PAK.
Cureus. 2021 Mar 12;13(3):e13852. doi: 10.7759/cureus.13852.
Chronic exposure to high levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) leads to metabolic complications, most importantly dysglycemia in the form of diabetes mellitus and pre-diabetes. Dysglycemia if diagnosed early in the course of the disease can decrease complications. Treatment modalities in the form of surgery and medical therapy have varied impacts on glucose metabolism.
To determine the frequency of diabetes mellitus, impaired glucose tolerance, and impaired fasting glucose in Pakistani patients with acromegaly and to establish the impact of the intervention (surgery/medical) on glucose metabolism.
This study was a retrospective review of patient records. Eighty-nine patients fulfilling the Endocrine Society criteria for acromegaly diagnosis were included. A data of baseline, GH, IGF-1 level, hemoglobin A1C (HbA1C), fasting blood glucose (FBG), and random blood glucose (RBS) levels were reviewed before and after the intervention (surgery/medical therapy). Normal glucose tolerance (NGT), impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes mellitus (DM) were defined based on the American Diabetes Association (ADA) criteria. Patients were grouped into normoglycemic (NGT) and dysglycemic (IFG, IGT, and DM) based on FBG, RBS, and HbA1C.
Major risk factors for dysglycemia included age (15-45 years), male sex (33.70%), obesity (45.7%), and macroadenoma (77.52%). Both mean GH levels (58.29 vs. 54.36 ng/dl) and IGF-1 levels (862.98 vs. 824.32 ng/dl) were higher among the normoglycemic than dysglycemia. Pre-surgery NGT, IFG, IGT, IFG, and IGT/DM combined were found in 48.31%, 5.61%, 1.1%, 5.61%, and 39.32% of the subjects respectively. Post-surgery, HbA1C improved in 79.5%, deteriorated in 6.8%, and remained the same in 13.6%. Similarly, it improved in 67% post-medical therapy. Both FBG and RBS improved post-surgery and medical therapy. Further, the number of anti-diabetic drugs used also decreased post-surgery.
Dysglycemia is more common among patients with acromegaly as compared to the general population and tends to be poorly controlled in untreated acromegaly. Glycemic control improves significantly after surgery and medical therapy.
长期暴露于高水平的生长激素(GH)和胰岛素样生长因子1(IGF-1)会导致代谢并发症,最重要的是以糖尿病和糖尿病前期形式出现的血糖异常。如果在疾病早期诊断出血糖异常,可减少并发症。手术和药物治疗等治疗方式对糖代谢有不同影响。
确定巴基斯坦肢端肥大症患者中糖尿病、糖耐量受损和空腹血糖受损的发生率,并确定干预措施(手术/药物)对糖代谢的影响。
本研究是对患者记录的回顾性分析。纳入89例符合内分泌学会肢端肥大症诊断标准的患者。回顾干预措施(手术/药物治疗)前后的基线数据、GH、IGF-1水平、糖化血红蛋白(HbA1C)、空腹血糖(FBG)和随机血糖(RBS)水平。根据美国糖尿病协会(ADA)标准定义正常糖耐量(NGT)、空腹血糖受损(IFG)、糖耐量受损(IGT)和糖尿病(DM)。根据FBG、RBS和HbA1C将患者分为血糖正常组(NGT)和血糖异常组(IFG、IGT和DM)。
血糖异常的主要危险因素包括年龄(15 - 45岁)、男性(33.70%)、肥胖(45.7%)和大腺瘤(77.52%)。血糖正常组的平均GH水平(58.29 vs. 54.36 ng/dl)和IGF-1水平(862.98 vs. 824.32 ng/dl)均高于血糖异常组。术前,分别有48.31%、5.61%、1.1%、5.61%和39.32%的受试者存在NGT、IFG、IGT、IFG以及IGT/DM合并情况。术后,79.5%的患者HbA1C改善,6.8%的患者恶化,13.6%的患者保持不变。同样,药物治疗后67%的患者HbA1C改善。术后和药物治疗后FBG和RBS均有所改善。此外,术后使用的抗糖尿病药物数量也减少。
与普通人群相比,肢端肥大症患者中血糖异常更为常见,未经治疗的肢端肥大症患者血糖往往控制不佳。手术和药物治疗后血糖控制显著改善。